search icon
Join IDSAJOIN IDSA >> Go to MyIDSAGO TO MYIDSA >>
  • Print
  • ShareThis
  • Text Size

IDSA Practice Guidelines

Practice guidelines are systematically developed statements to assist practitioners and patients in making decisions about appropriate health care for specific clinical circumstances. [Institute of Medicine Committee to Advise the Public Health Service on Clinical Practice Guidelines, 1990]

Attributes of good guidelines include validity, reliability, reproducibility, clinical applicability, clinical flexibility, clarity, multidisciplinary process, review of evidence, and documentation. [Institute of Medicine Committee to Advise the Public Health Service on Clinical Practice Guidelines, 1990]

Keyword Search

...

Search Results

27 results found

Nontuberculous Mycobacterial (NTM) Diseases

Status: Update in Progress

The minimum evaluation of a patient suspected of nontuberculous mycobacterial (NTM) lung disease should include the following: (1) chest radiograph or, in the absence of cavitation, chest high-resolution computed tomography

The minimum evaluation of a patient suspected of nontuberculous mycobacterial (NTM) lung disease should include the following: (1) chest radiograph or, in the absence of cavitation, chest high-resolution computed tomography (HRCT) scan; (2) three or more sputum specimens for acid-fast bacilli (AFB) analysis; and (3) exclusion of other disorders, such as tuberculosis (TB). Clinical, radiographic, and microbiologic criteria are equally important and all must be met to make a diagnosis of NTM lung disease. *For information on the timing of future updates to this guideline, contact the ATS.

Lyme Disease

Status: Update in Progress

Lyme disease is the most common tick-borne infection in both North America and Europe. In the United States, Lyme disease is caused by Borrelia burgdorferi, which is transmitted by the

Lyme disease is the most common tick-borne infection in both North America and Europe. In the United States, Lyme disease is caused by Borrelia burgdorferi, which is transmitted by the bite of the tick species Ixodes scapularis and Ixodes pacificus. Clinical manifestations most often involve the skin, joints, nervous system, and heart. Full textApproximately every 12 – 18 months following publication, IDSA evaluates its guidelines for the need for update.  Because several years have passed since the last update, IDSA determined that a new undertaking for Lyme disease guidelines was needed. In order to develop a more focused and manageable guideline than the previous guideline which had a very broad scope, the IDSA has decided to approach this guideline topic differently by separating the topic into distinct guidelines.  This is a practice that IDSA has implemented across many of its guidelines where the scope has been expansive. The first of these guideline topics to be addressed will be on the prevention, diagnosis, and treatment of Lyme disease.  This guideline is being developed jointly with the American Academy of Neurology and the American College of Rheumatology.  Other collaborators on the guideline include panel members from the following: American Academy of Family Physicians (AAFP), American Academy of Pediatrics – Committee on Infectious Diseases (AAP-COID), American Academy of Pediatrics – Section on Emergency Medicine (AAP-EM), American College of Physicians (ACP), Association of Medical Microbiology and Infectious Diseases – Canada (AMMI-CA), Child Neurology Society (CNS), Pediatric Infectious Diseases Society (PIDS), Entomological Society of America (ESA), European Society of Clinical Microbiology and Infectious Diseases (ESCMID).  Individuals from the disciplines of cardiology, microbiology and pathology as well as a consumer representative and a methodologist with expertise in GRADE are also among the members of the guideline development panel. In contrast to the 2006 IDSA guidelines, this guideline will not provide comprehensive coverage of Anaplasma phagocytophilum and Babesia microti outside the context of co-infections. Those pathogens will be treated more comprehensively in separate, forthcoming clinical guidelines. Information on the status of these updates can be found here, within the Practice Guidelines/Infections by Organism/Bacteria section of the IDSA website. *Projected publication, Fall 2018

Asymptomatic Bacteriuria

Status: Update in Progress

The purpose of this guideline is to provide recommendations for diagnosis and treatment of asymptomatic bacteriuria in adult populations 18 years of age. The recommendations were developed on the basis

The purpose of this guideline is to provide recommendations for diagnosis and treatment of asymptomatic bacteriuria in adult populations 18 years of age. The recommendations were developed on the basis of a review of published evidence, with the strength of the recommendation and quality of the evidence graded using previously described Infectious Diseases Society of America (IDSA) criteria (table 1) [1]. Recommendations are relevant only for the treatment of asymptomatic bacteriuria and do not address prophylaxis for prevention of symptomatic or asymptomatic urinary infection. This guideline is not meant to replace clinical judgment.Screening of asymptomatic subjects for bacteriuria is appropriate if bacteriuria has adverse outcomes that can be prevented by antimicrobial therapy [2]. Outcomes of interest are short term, such as symptomatic urinary infection (including bacteremia with sepsis or worsening functional status), and longer term, such as progression to chronic kidney disease or hypertension, development of urinary tract cancer, or decreased duration of survival. Treatment of asymptomatic bacteriuria may itself be associated with undesirable outcomes, including subsequent antimicrobial resistance, adverse drug effects, and cost. If treatment of bacteriuria is not beneficial, screening of asymptomatic populations to identify bacteriuria is not indicated, unless performed in a research study to further explore the biology or clinical significance of bacteriuria. Thus, there are 2 topics of interest: whether asymptomatic bacteriuria is associated with adverse outcomes, and whether the interventions of screening and antimicrobial treatment improve these outcomes.Full textA correction has been published: Clin Infect Dis (2005) 40 (10): 1556. *Projected publication, Fall 2018

Outpatient Parenteral Anti-Infective Therapy (OPAT)

Status: Update in Progress

These guidelines were formulated to assist physicians and other health care professionals with various aspects of the administration of outpatient parenteral antimicrobial therapy (OPAT). Although there are many reassuring retrospective

These guidelines were formulated to assist physicians and other health care professionals with various aspects of the administration of outpatient parenteral antimicrobial therapy (OPAT). Although there are many reassuring retrospective studies on the efficacy and safety of OPAT, few prospective studies have been conducted to compare the risks and outcomes for patients who receive treatment as outpatients rather than as inpatients. Because truly evidence-based studies are lacking, the present guidelines are formulated from the collective experience of the committee members and advisors from related organizations.  Full text*Projected Publication, Spring 2018

Directrizes Praticas da Infectious Disease Society

Status: Update in Progress

Estas diretrizes baseadas em evidências para o manejo de infecções por Staphylococcus aureusresistentes à meticilina (MRSA) foram preparadas por um grupo de especialistas da >Infectious Diaseases Society of America (IDSA). As

Estas diretrizes baseadas em evidências para o manejo de infecções por Staphylococcus aureusresistentes à meticilina (MRSA) foram preparadas por um grupo de especialistas da >Infectious Diaseases Society of America (IDSA). As diretrizes destinam-se a profissionais de saúde que atendem a pacientes adultos e crianças com infecções por MRSA. Elas discutem o manejo de várias síndromes clínicas associadas à doença por MRSA, inclusive as infecções de pele e partes moles (IPPM), a bacteremia e a endocardite, a pneumonia, as infecções ósseas e articulares e do sistema nervoso central (SNC). São feitas recomendações quanto à dosagem e monitoramento da vancomicina, ao manejo das infecções por cepas de MRSA com susceptibilidade reduzida à vancomicina e das falhas terapêuticas da vancomicina.

Neutropenic Patients with Cancer- Turkish

Status: Update in Progress

Bu belgegüncellemeleri veilkAmerikaEnfeksiyon HastalıklarıDerneği (IDSA)Ateş ve1997 yılında yayınlananveilkkez2002 yılındagüncellendiNötropeniYönergegenişletir.Kanserli hastalardakemoterapi ile indüklenenateş venötropenideneyimyönetmekantimikrobiyal ajanlarınkullanımı içinbir kılavuz olaraktasarlanmıştır.

Bu belgegüncellemeleri veilkAmerikaEnfeksiyon HastalıklarıDerneği (IDSA)Ateş ve1997 yılında yayınlananveilkkez2002 yılındagüncellendiNötropeniYönergegenişletir.Kanserli hastalardakemoterapi ile indüklenenateş venötropenideneyimyönetmekantimikrobiyal ajanlarınkullanımı içinbir kılavuz olaraktasarlanmıştır.

Influenza Spanish

Status: Update in Progress

Directricespara el tratamiento depersonas con infección porvirus de la influenzafueron elaboradas por unpanel de expertos dela Sociedad de EnfermedadesInfecciosas de Estados Unidos.Las directricesbasadas en pruebasabarcantemasde diagnóstico,tratamiento y la quimioprofilaxiscon medicamentos

Directricespara el tratamiento depersonas con infección porvirus de la influenzafueron elaboradas por unpanel de expertos dela Sociedad de EnfermedadesInfecciosas de Estados Unidos.Las directricesbasadas en pruebasabarcantemasde diagnóstico,tratamiento y la quimioprofilaxiscon medicamentos antivirales,y las cuestionesrelacionadas con la gestióninstitucional para elbroteestacional (ínter)de la influenza.Que están destinadospara uso de médicosentodas las especialidades médicas, conatención directa al paciente,ya que la infeccióndel virus de influenzaes común enlas comunidadesdurante la temporada degripey puede serencontradopor los médicosel cuidado deuna amplia variedad depacientes. Enlace al texto completo

Fever & Neutropenia

Status: Update in Progress

"好中球減少を呈する癌患者に対する"本稿は、米国感染症学会(Infectious Diseases Society of America;IDSA)が1997 年に公表し、2002 年に初回改訂を行った最初の発熱性好中球減少患者に対するガイドラインを更新・拡充するものである。化学療法により引き起こされた発熱性好中球減少症を呈する癌患者の管理の際の抗微生物薬の使用指針として活用されることを意図している。

"好中球減少を呈する癌患者に対する"本稿は、米国感染症学会(Infectious Diseases Society of America;IDSA)が1997 年に公表し、2002 年に初回改訂を行った最初の発熱性好中球減少患者に対するガイドラインを更新・拡充するものである。化学療法により引き起こされた発熱性好中球減少症を呈する癌患者の管理の際の抗微生物薬の使用指針として活用されることを意図している。

Candidiases Spanish

Status: Update in Progress

"Guías de práctica clínica para el manejo de la candidiasis: actualización del 2009, de la Infectious Diseases Society of America"[ektdesignns_placeholder_ID0ENC]

"Guías de práctica clínica para el manejo de la candidiasis: actualización del 2009, de la Infectious Diseases Society of America"[ektdesignns_placeholder_ID0ENC]

C. Difficile- French

Status: Update in Progress

"Directives concernant la pratique clinique en cas d’infection à Clostridium difficile chez l’adulte : Mise à jour 2010 effectuée par la « Society for Healthcare Epidemiology of America (ou SHEA)

"Directives concernant la pratique clinique en cas d’infection à Clostridium difficile chez l’adulte : Mise à jour 2010 effectuée par la « Society for Healthcare Epidemiology of America (ou SHEA) [Société américaine d’épidémiologie hospitalière] et la « Infectious Diseases Society of America (ou IDSA)"Cette ligne directriceest conçue pour améliorerle diagnostic et letraitement de l'infectionà Clostridium difficile(ICD)chez les patients adultes.Un cas deCDIest définie parla présence de symptômes(généralementla diarrhée) etsoit un testde selles positifspour les toxinesde C. difficileou toxigènesde C. difficile,ou les conclusionscoloscopieou histopathologiquerévélantune colitepseudo-membraneuse.En plus dediagnostic et de gestion, les méthodesrecommandées decontrôle des infections etla gestion environnementale del'agent pathogènesont présentés.Lesrecommandations sont fondées surles meilleures preuves disponibleset des pratiques, tel que déterminépar uncomité d'expertsnommés parcommunede karité et del'Infectious Diseases Societyof America(IDSA) (le Groupe d'expertsSHEA-IDSA).L'utilisation de ceslignes directrices peuventêtre touchés parla taille de l'établissement et des ressources, tant financièreset de laboratoire,disponiblesdans le cadreclinique particulière.

| HIVMA | Contact Us

© Copyright IDSA 2017 Infectious Diseases Society of America

Full Site Mobile Site